<DOC>
	<DOC>NCT01474863</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis is that intravenous L-citrulline will decreased the development or progression of acute lung injury in patients with severe sepsis compared to placebo.</brief_summary>
	<brief_title>Citrulline in Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<criteria>Severe Sepsis No Consent Malignant or other irreversible condition Moribund and not expected to survive 48 hours End Stage Liver Disease Enrolled in another IND study Pregnant or breast feeding female Age&lt;13 years old Allergy to citrulline or arginine</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>